Amwell®, (NYSE: AMWL) a national telehealth leader, today announced the appointment of Brendan O’Grady to the position of Chief Commercial & Growth Officer, effective immediately. Mr. O’Grady will report to Amwell’s Chairman and Co-CEO Ido Schoenberg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005157/en/
Brendan O’Grady (Photo: Business Wire)
“Brendan has been a meaningful contributor to Amwell’s strategy and growth since joining our Board in 2015,” said Ido Schoenberg, Chairman and Co-CEO. “His long and impressive track record successfully leading large scale growth in sizable healthcare organizations fits well with our plans. Having had the benefit of seeing his impact as a Board member, we are confident he understands our company, mission, and the tremendous opportunity ahead.”
In his new role, Mr. O’Grady will be responsible for driving strategic growth initiatives and leading the business development, sales and commercial enablement, marketing, channel partner, and account management teams. He will support the expansion of Amwell’s strategy across geographies and new markets, as well as identify new pathways for growth.
Mr. O’Grady joins the Company with over 30 years of experience in the healthcare sector, bringing a successful track record of growing and scaling large organizations. Much of his career has concentrated on creating and implementing innovative solutions and teams to drive organizational growth and to advance healthcare access through medicine. In his most recent role, Mr. O’Grady served as President and CEO of Teva Pharmaceuticals’ North America Business, where he was responsible for managing and scaling the productivity, profitability, and overall growth of all Teva’s North American business operations.
Mr. O’Grady commented, “Amwell has done an incredible job growing into one of healthcare’s most distinct, impactful companies, sitting at the center of care delivery. I am excited to join Ido, Roy and the team full-time with an eye on growing the company’s presence in familiar ways and exploring the unique opportunity that comes with the company’s deep connections to all the major players in healthcare, from providers, to insurers, employers and innovators.”
Prior to his role as President and CEO of Teva Pharmaceuticals’ North America business, Mr. O’Grady served as Chief Commercial Officer for Teva Pharmaceutical’s Global Specialty Medicine division and the interim head of Teva’s European Specialty business. Mr. O’Grady also held the positions of President & CEO of North America Generic Medicines and Senior Vice President and Head of US Market Access & Patient Services for Teva’s U.S. specialty business. Prior to joining Teva, O’Grady spent 10 years with Sanofi predecessor companies in a variety of commercial and medical affairs roles. In addition to serving on Amwell’s board since 2015, Mr. O’Grady has served as a board member for the Association of Accessible Medicines and most recently as a board member of the Pharmaceutical Research Manufacturers of America (commonly known as PhRMA).
Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives. For more information, please visit https://business.amwell.com/.
American Well, Amwell, Converge and Carepoint are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: weak growth and increased volatility in the telehealth market; inability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under ‘Risk Factors’ in our Form 10-K filed with the SEC on March 26, 2021. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of our website at investors.amwell.com and on the SEC’s website at www.sec.gov.